Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

HMB-002

Other · developed by Hemab ApS

Phase 1/2 Most advanced trial

COAG Developer

1 Registered trials

What is HMB-002?

HMB-002 is an agent administered subcutaneously and studied in von Willebrand disease, including types 1, 2 and 3.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Hematology
Developer: Hemab ApS (COAG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: DM6XM9P63V

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06754852	Phase 1/2	Von Willebrand Disease (VWD)	Recruiting	COAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Von Willebrand Disease (VWD)Von Willebrand Disease (VWD), Type 1Von Willebrand Disease (VWD), Type 2Von Willebrand Disease (VWD), Type 3

More from Hemab ApS

HMB-001 Phase 1/2 HMB-003 Phase 1 Sutacimig Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the COAG page.

Follow COAG, the company behind HMB-002

See COAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COAG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z